엘앤씨바이오

290650KOSDAQ의약품 제조업

50.6 / 100

Reference Date: 2026-04-13

Financial Score16.5 / 40

News Sentiment16.1 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 12.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

L&N Bio is a specialist in regenerative medicine, developing and selling human tissue implants and medical devices, along with cosmetic and pharmaceutical businesses. Its flagship product, Acellular Dermal Matrix (MegaDerm), is used for breast reconstruction after cancer treatment, and the company expands its global market by exporting tissue-based medical devices. It aims to grow into a comprehensive healthcare platform through R&D in regenerative medicine.

Number of Employees

155people

Average Salary

49.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

8.30Industry Average 1.040.0Point

8.0x industry avg (risky)

ROE

-55.32Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

4.94Industry Average 11.986.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.6% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲3.3% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 14.6% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 3Neutral 1Negative 0Average Sentiment Score 75

Positive
스킨부스터 규제 강화 앞둔 정부…엘앤씨바이오 ‘선제 대응’ 강조
엘앤씨바이오가 정부의 인체조직 스킨부스터 관리 강화 논의에 대해 선제적으로 제도 보완사항을 반영해 운영하고 있다고 밝혔습니다.
Positive
엘앤씨바이오 "인체조직 스킨부스터 ‘리투오’, 제도 보완사항 선제.....
엘앤씨바이오가 인체조직 스킨부스터 '리투오'와 관련하여 글로벌 사례, 안전관리, 환자 고지까지 준비 완료했다고 강조했습니다.
Neutral
셀트리온 손잡은 고바이오랩 '上'…ECM 스킨부스터 관심 계속[바이오....
고바이오랩의 기술수출과 녹십자웰빙의 ECM 스킨부스터 출시 소식 등 다른 바이오 기업들의 주가 상승에 대한 뉴스입니다.

Detailed Momentum

52-week position5.0Point

52w mid range (50%)

Current 69,700Won52-week high 118,30052-week low 20,400

1-month return1.0Point

1m -12.44% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral기업가치제고계획(자율공시)2026-04-01
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral정기주주총회결과2026-03-31
Neutral주식등의대량보유상황보고서(일반)2026-03-26
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-26